Skip to contentF
Filana Therapeutics, Inc.
F
FLNAFilana Therapeutics, Inc. Q3 2015 · 10-Q
Revenue—
Net Income-$3.67M-$3.67MN/M vs Q3 2014 EPS Diluted-$0.08-$0.08N/M vs Q3 2014 Operating Income-$3,686,000N/M Operating Cash Flowderived-$2,410,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Filana Therapeutics, Inc. · CIK 1069530 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,410,000N/M ended Sep 30, 2015 · filed Nov 9, 2015 · 40 d after period end